Several phases, I and II, clinical studies have shown that CD133+ stem cell application for the treatment of various diseases (e.g., liver disease, critical limb ischemia, amyotrophic lateral sclerosis, spinal cord injuries, cerebral palsy, chronic ischemic cardiomyopathy, and leukaemia) is safe and feasible [10, 55–65]. The gene discussed is PROM1; the disease is amyotrophic lateral sclerosis.